Alnylam defends against Tekmira complaint.

Alnylam defends against Tekmira complaint, files answer and counterclaim Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, has filed an answer and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation available Litigation Program of the Massachusetts Superior Court. ‘Our focus remains on the advancement of RNAi therapeutics to patients and execution on our medical programs.’.‘The results of the RADICAL research and the economic analysis recommend the Abbott technology provides actionable information much earlier, allow physicians to boost patient outcomes and may ultimately lower general health care costs related to these serious infections. ‘ Each full year, sepsis affects more than 26 million people worldwide. The fast-moving bloodstream infections is considered the priciest in-hospital condition, costing a lot more than $20 billion each year in the U.S.5 billion in the united kingdom. Abbott has developed a platform based on PCR/ESI-MS technology with the target to deliver a broad range of assessments that can identify a huge selection of bacteria, fungi and infections directly from a patient specimen within eight hours.